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RESEARCH ARTICLE Open Access
Ciprofloxacin resistance in community- and
hospital-acquired Escherichia coli urinary
tract infections: a systematic review and
meta-analysis of observational studies
Oyebola Fasugba1*, Anne Gardner1, Brett G. Mitchell1,2 and George Mnatzaganian3
Abstract
Background: During the last decade the resistance rate of urinary Escherichia coli (E. coli) to fluoroquinolones such as
ciprofloxacin has increased. Systematic reviews of studies investigating ciprofloxacin resistance in community- and
hospital-acquired E. coli urinary tract infections (UTI) are absent. This study systematically reviewed the literature and
where appropriate, meta-analysed studies investigating ciprofloxacin resistance in community- and hospital-acquired
E. coli UTIs.
Methods: Observational studies published between 2004 and 2014 were identified through Medline, PubMed,
Embase, Cochrane, Scopus and Cinahl searches. Overall and sub-group pooled estimates of ciprofloxacin resistance
were evaluated using DerSimonian-Laird random-effects models. The I2 statistic was calculated to demonstrate the
degree of heterogeneity. Risk of bias among included studies was also investigated.
Results: Of the identified 1134 papers, 53 were eligible for inclusion, providing 54 studies for analysis with one paper
presenting both community and hospital studies. Compared to the community setting, resistance to ciprofloxacin was
significantly higher in the hospital setting (pooled resistance 0.38, 95 % CI 0.36-0.41 versus 0.27, 95 % CI 0.24-0.31 in
community-acquired UTIs, P < 0.001). Resistance significantly varied by region and country with the highest resistance
observed in developing countries. Similarly, a significant rise in resistance over time was seen in studies reporting on
community-acquired E. coli UTI.
Conclusions: Ciprofloxacin resistance in E. coli UTI is increasing and the use of this antimicrobial agent as empirical
therapy for UTI should be reconsidered. Policy restrictions on ciprofloxacin use should be enhanced especially in
developing countries without current regulations.
Keywords: Antimicrobial resistance, Escherichia coli, Urinary tract infection, Systematic review, Meta-analysis
Background
Urinary tract infections (UTI) are one of the most frequent
bacterial infections affecting people both in the community
and in hospitals [1]. It is estimated that about 150 million
people per annum are diagnosed with UTI worldwide [2].
A recent World Health Organisation (WHO) report on
antimicrobial resistance (AMR) surveillance specified nine
bacteria of international concern which are responsible for
some of the most common infections in community and
hospital settings [3]. Escherichia coli (E. coli), the pathogen
most often implicated in UTIs, is listed as one of the nine.
In all six WHO regions (Africa, Americas, Eastern Mediter-
ranean, European, South-East Asia and Western Pacific)
high rates of antimicrobial resistance have been observed in
this pathogen [3].
Ciprofloxacin is the most commonly prescribed
fluoroquinolone for UTIs because it is available in oral
and intravenous preparations [4]. It is well absorbed
from the gastrointestinal tract after oral administration.
It also has a documented safety profile, broad Gram
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negative organism coverage and high urinary excretion
rate [4]. During the last decade the resistance rate of E.
coli to fluoroquinolones such as ciprofloxacin has in-
creased [5]. A 10 year analysis of urinary E. coli speci-
mens in Switzerland, found an increasing trend in
resistance to ciprofloxacin, from 1.8 to 15.9 % [6]. Fluor-
oquinolones are ranked as one of four of the highest pri-
ority critically important antimicrobials [7] as they have
an important role in the treatment of more severe infec-
tions, such as septicaemia. Therefore resistance to fluor-
oquinolones can have serious clinical consequences.
They are one of few available therapies for serious
Salmonella spp. and E.coli infections [5]. Resistance to
fluoroquinolones emerges quickly, and this is likely to be
related to the biology of resistance as well as a direct re-
sponse to drug pressure [8]. They should therefore be
used with caution and reserved for severe infections,
and preceded by antimicrobial susceptibility testing of
the bacteria involved [5]. The most recent Infectious
Diseases Society of America (IDSA) guidelines recom-
mend that fluoroquinolones should be reserved for
important uses due to their propensity for ecological un-
favorable effects of antimicrobial therapy such as the se-
lection of drug-resistant pathogens and colonisation or
infection with multidrug-resistant organisms [9].
Recent prescribing guidelines recommend reserving
ciprofloxacin use for more severe infections and resist-
ance to this agent is increasing prompting further re-
search in this area [6, 10, 11]. Published quantitative
syntheses of overall ciprofloxacin-resistant E. coli UTI
prevalence and incidence in hospital and community set-
tings are absent. This systematic review of observational
studies therefore aims to compare ciprofloxacin resist-
ance in both settings. Knowledge about ciprofloxacin re-
sistance in community- and hospital-acquired E. coli
UTIs will provide information for control of resistant
pathogens. This review also has the potential to provide
a basis for which future interventions can be evaluated.
The findings will, in addition, make available informa-
tion on ciprofloxacin resistance in various regions of the
world providing some evidence for further regulatory
control of ciprofloxacin use globally.
Methods
Protocol and registration
The protocol for conducting this review has been regis-
tered and can be accessed on the International prospect-
ive register of systematic reviews (PROSPERO) (available
at http://www.crd.york.ac.uk/prospero/ with registration
number: CRD42014014473). Prior to registration, the
protocol was reviewed by a reviewer external to the
study team. Ethics approval was not sought as this re-
view synthesized data from published studies for which
approval had already been obtained.
Search strategy
We conducted a systematic review of observational (cross
sectional, cohort and case control) studies published in
the last 11 years (2004–2014) reporting on ciprofloxacin
resistance in community- and hospital-acquired E. coli
UTIs. This time limit is based on changes in the micro-
biology and epidemiology of antimicrobial resistant patho-
gens which occurred in the past decade with subsequent
changes in treatment regimens and patient outcomes [12].
Reporting of this review complied with the preferred
reporting items for systematic reviews and meta-analyses
(PRISMA) [13].
The electronic bibliographic databases MEDLINE/
PubMed, EMBASE, Cochrane, CINAHL and Scopus were
searched. Searches were conducted for words in the title or
abstract or within the full text of the papers. These included
both keywords only and keywords with medical subject
headings (MeSH) using the search terms ‘resistance’, ‘urinary
tract infection’ and ‘Escherichia coli’ from 1st January 2004
to 31st December 2014 (see Additional file 1). The refer-
ence lists of papers identified from the electronic databases
were hand-searched for additional papers.
Inclusion and exclusion criteria
Papers were included if they reported prevalence or inci-
dence rates of ciprofloxacin resistance in community- or
hospital-acquired E. coli UTIs. Papers reporting on urinary
E. coli ciprofloxacin susceptibility in which resistance rate
could be calculated were also included. We included pa-
pers involving adults and/or children. Only peer reviewed
manuscripts were considered. Grey material which in-
cludes unpublished literature, conference abstracts, letters
to editors, newsletters and reports were excluded. Non-
peer reviewed literature were also excluded. Papers
written in languages other than English were also excluded.
In addition, papers not clearly specifying the setting
(hospital-acquired or community-acquired); drug (cipro-
floxacin) or sample (urine) were excluded. Papers that
focused on specific sub-populations (e.g. diabetics and pa-
tients with recurrent UTI) were also excluded as these did
not represent the general population. This review included
only papers that used the Centers for Disease Control and
Prevention (CDC) definition of microbiologically confirmed
UTI (≥105 colony forming unit/ml) [14].
Definitions
For the purpose of this review, a study was defined as all
data from a published paper with the only distinction be-
ing ‘hospital’ or ‘community’ setting. Therefore, if a single
paper meeting the eligibility criteria reported data on both
settings, they were included as two separate studies.
Community-acquired UTI was defined as positive sam-
ples obtained from (i) outpatient clinics; (ii) general prac-
tice (GP) clinics; (iii) emergency departments; (iv) within
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48 h of hospital admission or (v) from nursing homes or
residential aged care facilities [15–17].
Hospital-acquired UTI was defined as positive samples
obtained (i) after 48 h of hospital admission or (ii) within
48 h of hospital discharge [15].
Important changes in healthcare delivery over the last
few years have seen some usually inpatient procedures
now more often than not performed on an outpatient
basis [18]. Patients transition freely within sometimes
loosely defined levels of the health care system, for ex-
ample between long-term care or rehabilitation services,
to acute-care centres [19, 20]. This study only considered
hospital-acquired UTIs as opposed to a wider definition of
healthcare associated UTIs, to avoid this confusion.
Study selection
The titles and abstracts of all papers identified in the elec-
tronic databases were examined and assessed for relevance
and appropriateness to the principal objective of the sys-
tematic review. Irrelevant studies were excluded. Full texts
of the potentially relevant papers were printed and care-
fully assessed against the systematic review inclusion and
exclusion criteria. Those not meeting the criteria were ex-
cluded. The remaining papers deemed to have data rele-
vant to the systematic review and meta-analysis were
assessed for quality and risk of bias.
The study selection process and other stages of the re-
view were performed by the lead author (OF). At each
stage, 10 % of papers identified were also screened
against the study criteria independently by other authors
(AG, GM and BM). Discrepancies in either the applica-
tion of inclusion or exclusion of papers, quality assess-
ment or on data extraction were discussed among all
authors to make the final decision.
Data extraction process
Data were extracted by one author (OF) and 10 % of pa-
pers eligible for data extraction were independently ex-
tracted by another author (AG). Data extraction was
compared between AG and OF demonstrating 100 %
agreement for all items except the study design. This
variable was therefore assessed by all authors. Where
there was missing information on the study design of pa-
pers to be included in the meta-analysis, attempts were
made to contact the authors. When there was no re-
sponse, consensus on the study design was reached by
all authors. Agreement between authors was assessed
using Kappa coefficient. The agreement between all au-
thors in deciding on the study design was 71 % (Kappa
(95 % CI) = 0.429 (0.154–0.703), P Value = 0.003). Papers
for which no agreement could be reached on the design,
based on insufficient information, were assigned as non-
classifiable. Any other missing information in the in-
cluded papers was recorded as ‘not stated’.
The first author, year of study, country of study, study
setting, age and sex distribution, co-morbidities, sample
size, study design, study aim, antimicrobial susceptibility
testing method, ciprofloxacin resistance rate, risk factors
for ciprofloxacin resistance (i.e. previous antibiotic use)
and mortality data (if reported) were extracted. Where
the ciprofloxacin resistance rate was not available, the
susceptibility rate was used to determine resistance.
Risk of bias in individual studies
Quality and risk of bias of the final papers included
in the review was conducted using a modified version
of the Newcastle-Ottawa Scale (NOS) which is a risk
of bias assessment tool for observational studies rec-
ommended by the Cochrane Collaboration [21, 22].
Content validity and inter-rater reliability of this tool
have been established [22]. Studies were rated by
assigning a judgment of ‘Low risk’ of bias, ‘High risk’
of bias, or ‘Unclear risk’ of bias according to pub-
lished criteria [21].
Statistical analysis
Pooled ciprofloxacin resistance proportions (with 95 %
confidence intervals) in patients with E. coli UTI were
separately calculated and compared between hospital
and community settings using a random-effects meta-
analysis model based on DerSimonian and Laird method
[23, 24]. This method incorporates an estimate of the
between-study variation into both the study weights and
the standard error of the estimate of the common effect.
The precision of an estimate from each included study
was represented by the inverse of the variance of the
outcome pooled across all studies. If the value of the
pooled prevalence was within the 95 % CI, then the ef-
fect size was statistically significant at the 5 % level (P <
0.05). The heterogeneity among studies was assessed by
using the I2 statistic with a P value of <0.05 considered
statistically significant, and I2 values below 25 % indicat-
ing low heterogeneity, 25–75 % moderate heterogeneity
and over 75 % high heterogeneity [25]. Subgroup ana-
lyses were done by risk of bias, study duration, age
group, UTI symptoms, world region and economy of
country (categorised as developed and developing using
the World Bank classification [26]). A meta-regression
analysis was used to determine the effect of measured
covariates on the observed heterogeneity in resistance
estimates across studies [23]. Assessment of publication
bias was estimated using funnel plots. Further analysis
was undertaken to examine pooled ciprofloxacin resist-
ance over time using the median study year. For studies
occurring over 2 years, the first year was used; for stud-
ies occurring over 4 years, the 2nd year was used; for
those over 6 years, the 3rd year was used. The non-
parametric Spearman’s rho correlation coefficient was
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calculated to determine significance in resistance trend
over time. Statistical analyses were undertaken using Stata
statistical softwareversion 13 [27].
Results
Study selection
Electronic database searches identified 15,062 potential
studies and 31 additional studies were identified through
hand searching. After 11,397 duplicates were removed,
3696 articles remained for title and abstract screening.
We assessed 1134 as potentially eligible and retrieved
the full text of these articles. After applying inclusion
and exclusion criteria, 53 papers (5 %) were deemed to
have data relevant to the systematic review and meta-
analysis. These 53 papers consisted of 54 studies com-
prising three hospital-acquired E. coli UTI studies and
51 community-acquired E. coli UTI studies. There was
one paper that compared resistance in both hospital and
community settings hence reported as two studies [15].
The PRISMA flow chart describing the papers identified
from the search strategy and reasons for exclusion is
shown in Fig. 1.
Study characteristics
Geographically, 53 of the 54 studies were carried out in
Asia (28 %; n = 15), Europe (24 %; n = 13), Middle East
(15 %; n = 8), Africa (13 %; n = 7), North America (11 %;
n = 6) and South America (7 %; n = 4). The remaining
study was conducted in multiple countries [28]. There
were 17 (31 %) studies conducted in developed countries
and 36 (67 %) in developing countries. The majority of
the studies (80 %) followed a cross sectional design. The
duration of studies ranged from 2 months to 84 months
(median = 15.5; IQR = 12.0-30.0). The mean age and sex
proportion of patients with an E. coli UTI were stated in
13 % (n = 7) and 44 % (n = 24) of studies respectively.
Most study populations included patients of both sexes al-
though 19 % (n = 10) included only women. Antimicrobial
susceptibility testing and interpretation was performed
using the disk diffusion method (74 %) and Clinical and
Laboratory Standards Institute (CLSI) criteria (83 %) re-
spectively in most studies. Table 1 provides further details
on the description of the included studies.
Pooled ciprofloxacin resistance
Figures 2 and 3 show the forest plots of studies report-
ing on ciprofloxacin resistance in community acquired
E. coli UTI by region and economy, respectively. Figure 4
shows the forest plot of studies reporting on ciprofloxacin
resistance in hospital acquired E. coli UTI. Compared with
the community-setting, resistance to ciprofloxacin in E
coli UTIs was significantly higher in the hospital-setting
(P < 0.001). Overall, the pooled rate for ciprofloxacin re-
sistance in patients with community-acquired E. coli UTIs
was 0.27 (95 % CI: 0.240-0.310), compared with 0.38
(95 % CI: 0.360-0.410) in the hospital setting. There was
substantial heterogeneity among the community-setting
studies (I2 = 98.8 %, P < 0.0001), but very little in the hos-
pital ones (I2 = <0.010 %, P = 0.641). Further analysis of
studies reporting on community-acquired E. coli UTI by
region (Fig. 3) showed that Asia had the highest pooled re-
sistance. Analysis by economy based on the World Bank
classification (Fig. 4) showed a higher pooled resistance in
developing countries.
Resistance over time in community-acquired UTI studies
Figure 5 shows the scatter plot of ciprofloxacin resistance
in 47 studies reporting on community-acquired UTI using
the median study year for each study. Four studies did not
provide data on the year(s) the study was conducted and
were excluded from this analysis [29–32]. The results of
the Spearman’s rho correlation test showed a statistically
significant rise in resistance over time (n = 47, rs =
0.431, P = 0.003). Similar findings were observed for devel-
oping countries. There was no significant rise in resistance
over time in developed countries.
Subgroup analyses
Sub-group analysis was conducted within each major
setting. For community-acquired UTI studies (Table 2),
there was a significant difference in the pooled resistance
within each subgroup examined (risk of bias, study dur-
ation, economy, region, age group and UTI symptoms).
The subgroup analyses results for studies reporting on
hospital-acquired E. coli UTI (see Additional file 2)
showed no difference in the pooled resistance within the
subgroups examined (region, economy and UTI symp-
toms). When both settings were compared (see Additional
file 3), there were significant differences noted for risk of
bias (high), study duration (>12 months), economy (devel-
oped), region (Americas), age group (adults and children)
and UTI symptoms (P < 0.001). There were no data avail-
able on mortality for comparison between settings.
Meta-regression analyses
Random effects meta-regression analyses of studies
reporting on community-acquired E. coli UTI showed
that country’s economy (P = 0.008), Asia as a region (P =
0.002), high risk of bias (P = 0.003), year of study (P =
0.020) and studies using only children as the study popu-
lation (P = 0.030) were the study factors significantly ac-
counting for the observed heterogeneity, responsible for
61 % of the between study variance (Adjusted R2) in cipro-
floxacin resistance.
Risk of bias
When studies were assessed for risk of bias using the
Newcastle-Ottawa scale, 30 % (n = 16) were assessed as
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having a low risk of bias; 22 % (n = 12) unclear risk of bias
and 48 % (n = 26) were deemed to have a high risk of bias.
Further analysis of the 16 low risk studies only was con-
sistent with findings reported from the analysis of all stud-
ies. An increasing resistance trend over time was also
observed, however this increase did not reach statistical
significance because of reduced statistical power.
Discussion
The findings of this systematic review and meta-analysis
highlight the higher ciprofloxacin resistance in hospital-
acquired E.coli UTI when compared to community-
acquired UTI. There is also substantial evidence that
ciprofloxacin resistance in community-acquired E. coli
UTI has been increasing in recent years. Resistance was
Fig. 1 PRISMA flow diagram of study selection. (*54 studies from 53 papers)
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Table 1 Description of studies included in meta-analysis
Study author Country Designa Setting Risk of bias Study durationb
(months)
Number of
positive E. coli
UTI samplesc
Number of
ciprofloxacin
resistant E. coli
Proportion resistant
(95 % CI)
Standard error Weightd (%)
Ahmad, 2012 India Cross sectional Community Unclear 24 318 48 0.15 (0.11, 0.19) 0.02 2.09
Akoachere et al., 2012 Cameroon Cross sectional Community Low 12 43 11 0.26 (0.13, 0.39) 0.07 1.61
Akram et al., 2007 India Cross sectional Community High 12 61 42 0.69 (0.57, 0.80) 0.06 1.70
AlSweih et al., 2005 Kuwait Cross sectional Community High 12 1535 81 0.05 (0.04, 0.06) 0.01 2.15
Al-Tawfiq et al., 2009 Saudi Arabia Cohort Community High 12 2281 592 0.26 (0.24, 0.28) 0.01 2.14
Ansbach et al., 2013 USA Cross sectional Community High 7 98 2 0.02 (−0.01, 0.05) 0.01 2.12
Arabi et al., 2013 Iran Cross sectional Community Low 33 103 23 0.22 (0.14, 0.30) 0.04 1.91
Araujo et al., 2011 Brazil Cross sectional Community Unclear 24 391 36 0.09 (0.06, 0.12) 0.01 2.12
Arslan et al., 2005 Turkey Cross sectional Community Low 5 514 135 0.26 (0.22, 0.30) 0.02 2.09
Astal, 2005 Palestine Cross sectional Community High 6 252 30 0.12 (0.08, 0.16) 0.02 2.09
Azap et al., 2010 Turkey Cohort Community Unclear 12 464 139 0.30 (0.26, 0.34) 0.02 2.08
Bahadin et al., 2011 Singapore Cross sectional Community Unclear 12 90 22 0.24 (0.16, 0.33) 0.05 1.86
Biswas et al., 2006 India Cross sectional Community High 36 354 124 0.35 (0.30, 0.40) 0.03 2.05
Bouchillon et al., 2013 USA Cross sectional Community High 24 723 234 0.32 (0.29, 0.36) 0.02 2.10
Bouchillon et al., 2013 USA Cross sectional Hospital High 24 253 103 0.41 (0.35, 0.47) 0.03 11.83
Dash et al., 2013 India Cross sectional Community Low 30 397 212 0.53 (0.48, 0.58) 0.03 2.05
Dimitrov et al., 2004 Kuwait Cross sectional Community High 84 780 92 0.12 (0.10, 0.14) 0.01 2.13
Farshad et al., 2011 Iran Cross sectional Community Low 12 90 8 0.09 (0.03, 0.15) 0.03 2.01
Ghadiri et al., 2012 Iran Cross sectional Hospital High 24 200 80 0.40 (0.33, 0.47) 0.03 9.41
Gobernado et al., 2007 Spain Cross sectional Community Low 12 2292 418 0.18 (0.17, 0.20) 0.01 2.14
Ho et al., 2010 Hong Kong Cross sectional Community Low 24 271 35 0.13 (0.09, 0.17) 0.02 2.09
Hoban et al., 2011 Multiple countries Cross sectional Hospital High 24 1643 624 0.38 (0.36, 0.40) 0.01 78.76
Ismaili et al., 2011 Belgium Cohort Community High 24 189 5 0.03 (0.00, 0.05) 0.01 2.13
Kashef et al., 2010 Iran Cross sectional Community High 30 578 180 0.31 (0.27, 0.35) 0.02 2.09
Kiffer et al., 2007 Brazil Cross sectional Community Unclear 48 22679 2699 0.12 (0.11, 0.12) 0.002 2.15
Killgore et al., 2004 USA Case–control Community Low 12 120 40 0.33 (0.25, 0.42) 0.04 1.89
Kimando et al., 2010 Kenya Cross sectional Community Unclear 6 92 6 0.07 (0.01, 0.12) 0.03 2.05
Kothari et al., 2008 India Cross sectional Community High 6 361 260 0.72 (0.67, 0.77) 0.02 2.06
Kurutepe et al., 2005 Turkey NC Community High 72 880 174 0.20 (0.17, 0.22) 0.01 2.12
Lau et al., 2004 Taiwan Cross sectional Community Unclear 13 80 14 0.17 (0.09, 0.26) 0.04 1.89
Ljuca et al., 2010 Bosnia & Herzegovina Cross sectional Community High 36 43 4 0.09 (0.01, 0.18) 0.04 1.87
Fasugba
et
al.BM
C
Infectious
D
iseases
 (2015) 15:545 
Page
6
of
16
Table 1 Description of studies included in meta-analysis (Continued)
Longhi et al., 2012 Italy NC Community Low 6 154 36 0.23 (0.17, 0.30) 0.03 1.98
Martinez et al., 2012 Colombia Cross sectional Community High 2 102 39 0.38 (0.29, 0.48) 0.05 1.83
Miragliotta et al., 2008 Italy Cohort Community Low 60 2589 422 0.16 (0.15, 0.18) 0.01 2.14
Molina-Lopez et al., 2011 México Cross sectional Community High 48 119 65 0.55 (0.46, 0.64) 0.05 1.86
Moreira et al., 2006 Brazil Cross sectional Community Unclear 15 544 65 0.12 (0.09, 0.15) 0.01 2.12
Murugan et al., 2012 India Cohort Community High 12 204 144 0.71 (0.64, 0.77) 0.03 2.00
Muvunyi et al., 2011 Rwanda Cross sectional Community Low 6 72 23 0.32 (0.21, 0.43) 0.05 1.75
Mwaka et al., 2011 Uganda Cross sectional Community High NS 27 9 0.33 (0.16, 0.51) 0.09 1.32
Ni Chulain et al., 2005 Ireland Cross sectional Community High 5 723 18 0.02 (0.01, 0.04) 0.01 2.15
Olson et al., 2012 USA Cross sectional Community Unclear 16 95 4 0.04 (0.00, 0.08) 0.02 2.08
Otajevwo, 2013 Nigeria Cross sectional Community High 6 5 4 0.80 (0.45, 1.15) 0.18 0.63
Prakash et al., 2013 India Cross sectional Community Low NS 23 16 0.70 (0.51, 0.88) 0.10 1.26
Randrianirina et al., 2007 Madagascar Cross sectional Community Low 28 607 100 0.16 (0.14, 0.19) 0.02 2.12
Rani et al., 2011 India Cross sectional Community Unclear 6 208 151 0.73 (0.67, 0.79) 0.03 2.01
Shaifali et al., 2012 India Cross sectional Community Unclear 12 46 28 0.61 (0.47, 0.75) 0.07 1.54
Shariff et al., 2013 India Cross sectional Community High 18 491 160 0.33 (0.28, 0.37) 0.02 2.08
Sire et al., 2007 Senegal Cross sectional Community Low 33 1010 157 0.16 (0.13, 0.18) 0.01 2.13
Sood et al., 2012 India NC Community High 30 214 160 0.75 (0.69, 0.81) 0.03 2.02
Stratchounski et al., 2006 Russia NC Community Low 48 423 18 0.04 (0.02, 0.06) 0.01 2.14
Vellinga et al., 2012 Ireland Case–control Community Low 9 633 78 0.12 (0.10, 0.15) 0.01 2.12
Wang et al., 2014 China Cross sectional Community High 8 129 91 0.71 (0.63, 0.78) 0.04 1.92
Yildirim et al., 2010 Turkey Cross sectional Community Unclear 24 450 85 0.19 (0.15, 0.23) 0.02 2.10
Yolbas et al., 2013 Turkey Cross sectional Community High 12 113 24 0.21 (0.14, 0.29) 0.04 1.93
aNon-classifiable design
bNot stated
cStudy denominator
dWeights are from random effects analysis using DerSimonian-Laird model
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also found to be significantly higher in developing coun-
tries reporting on E. coli UTI in community settings.
Antimicrobial resistance has been described as an inter-
national hazard to public health threatening the successful
prevention and treatment of bacterial, viral, parasitic and
fungal infections [3, 33]. As such, research into its
prevention and reduction is very important. Our esti-
mated pooled ciprofloxacin resistance of 27 and 38 % in
community- and hospital-acquired E. coli UTI respectively
could not be compared to any other systematic review
findings because, to our knowledge, this is the first sys-
tematic review and meta-analysis comparing ciprofloxacin
NOTE: Weights are from random effects analysis
.
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resistance in community- and hospital-acquired E. coli
UTI. However, national data from five WHO regions show
at least 50 % resistance to fluoroquinolones (ciprofloxacin,
norfloxacin or ofloxacin) in E. coli [3]. Data on E. coli in
the WHO report are from various settings and sources
(including blood and urine) hence cannot be directly com-
pared with the results from our systematic review. An-
other recent review on global fluoroquinolone resistance
NOTE: Weights are from random effects analysis
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epidemiology reported a range of 2 to 69 % for fluoro-
quinolone resistance in uncomplicated community-
acquired UTI and up to 98 % in complicated cases, with
fluoroquinolone resistance in healthcare associated UTIs
ranging from 6 to 62 % [34]. The findings from our sys-
tematic review are within the above reported ranges.
However, the latter ranges were wide and the data were
from a number of different Gram negative uropathogens
and not specifically E. coli accounting for the higher rates.
Available published data show relatively high rates of urin-
ary E. coli resistance to ciprofloxacin [35–41] prompting
the need for a renewed effort in the further prevention of
spread of resistance to this antimicrobial agent.
We found that urinary E. coli resistance to ciprofloxa-
cin was higher in the hospital compared to the commu-
nity setting. Our finding is comparable to individual
studies which have assessed urinary E.coli resistance to
ciprofloxacin in both, hospital and community settings
[31, 41–45]. However, often studies do not apply the cri-
terion of 48 h post admission used in our systematic re-
view for identifying hospital acquired UTI [45, 46]. The
Canadian national surveillance study (CANWARD), a
large population-based study undertaken from 2007 to
2009, further confirms our finding of higher resistance
in the hospital setting [47]. Inpatients had a significantly
higher urinary E. coli resistance to ciprofloxacin. Similar
findings were reported by Cullen et al. in Dublin [16].
This is not an unusual finding and may be attributed to
the selective pressure resulting from antimicrobial use in
hospital settings [47]. Patients in hospital, already acutely
ill, become more at risk of developing a resistant infec-
tion because of potential immune deficiency and relative
high exposure to antimicrobial agents [48]. Furthermore,
hospitalized patients are more likely to be exposed to
practices that result in cross infection or transmission of
organisms. These and other risk factors enable the
spread of resistance. This has significant implications for
patient care as antimicrobial resistance may lead to
treatment failure resulting in death.
The results of our systematic review showed a signifi-
cant rise in resistance over time in the community set-
ting. This finding is supported by a number of US-based
studies investigating antimicrobial resistance trend in
outpatients. A fivefold increase (from 3 to 17.1 %) in cip-
rofloxacin resistance was observed from 2000 to 2010 by
Sanchez et al. [17] in comparison with other antibiotics
investigated [49]. Our findings are also consistent with
Blaettler et al. [6] who found that over a 10 year period
(1997–2007), similar to the timeframe for our review, re-
sistance increased significantly for ciprofloxacin from 1.8
to 15.9 % in Switzerland. This increase coincided with a
rise in ciprofloxacin use in Switzerland [6]. These find-
ings suggest that with increase in the use of fluoroquino-
lones generally over time, resistance ciprofloxacin is
likely to further increase. It is now known that anti-
microbial overuse or misuse is a risk factor for the devel-
opment of AMR [50]. The specific effect of ciprofloxacin
use on the development of its resistance in UTI patho-
gens is also clearly documented. A recent Irish study in-
volving 72 general practices found higher ciprofloxacin
resistance levels (5.5 %) in practices with 10 prescrip-
tions per month compared with resistance levels of 3 %
in practices with one prescription per month [51]. Wide
spread use of this agent may have thus resulted in a rise in
ciprofloxacin resistance. In the Netherlands and United
States, an association has also been shown between high
Table 2 Subgroup analyses of pooled ciprofloxacin resistance in community setting
Subgroup Community Setting N = 51 P value*
Pooled resistance
Risk of bias Low and unclear n = 28 studies 0.221 <0.0001
High n = 23 studies 0.337
Study durationa ≤12 monthsn = 25 studies 0.323 <0.0001
>12 monthsn = 24 studies 0.219
Economy Developedn = 16 studies 0.141 <0.0001
Developingn = 35 studies 0.345
Region Africa, Asia and Middle Eastn = 29 studies 0.361 <0.0001
Europe, North and South American = 22 studies 0.174
Age groupa Adults and children bn = 24 studies 0.265 <0.0001
Adults onlyn = 19 studies 0.302
UTI symptoms Symptomatic and asymptomatic patients n = 11 studies 0.185 <0.0001
Symptomatic patients only n = 40 studies 0.295
n = number of studies reporting on community acquired UTI
*Comparing pooled resistance for difference in subgroup in community setting
aStudies with missing information on this sub-analysis were not included
bStudies reporting resistance in adults and children or children only
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fluoroquinolone prescriptions and a rise in bacterial resist-
ance [52, 53]. Furthermore, changes in antimicrobial pre-
scribing practices have been shown to precede changes in
resistance rates. A study by Gottesman et al. [54] in Israel
found a significant decrease in E. coli resistance to cipro-
floxacin following a nationwide restriction on cipro-
floxacin use. Resistance decreased from 12 % in the
pre-intervention period to 9 % in the intervention period.
Our results pose a strong argument for the development
of more stringent criteria limiting ciprofloxacin use. In
addition, other strategies such as adequate surveillance
and monitoring, reinforcement of existing infection pre-
vention and control measures as well as new technological
advancement will help reduce the widespread problem of
antimicrobial resistance [55–57] but these aspects are not
within the scope of this paper.
Our finding of a significant rise in resistance over time
also has implications for the development of treatment
guidelines. The national recommendations for first-choice
empiric antibiotic treatment of UTIs vary considerably [5].
In countries like Spain, Taiwan and Turkey, the treatment
choice for uncomplicated UTIs are fluoroquinolones [5, 58,
59]. In 2000, fluoroquinolones were prescribed for treat-
ment of uncomplicated UTIs in Switzerland in 64 % of
cases [60]. There is concern that resistance to ciprofloxacin
resulting from its first-line use may be associated with an
increase in multidrug resistance [61]. The most recent IDSA
guidelines [9] advise using nitrofurantoin, trimethoprim-
sulphamethoxazole, fosfomycin or pivmecillinam for
first-line treatment of acute uncomplicated cystitis. Fluor-
oquinolones should be reserved for important uses other
than acute cystitis or used as an alternative only when
these recommended agents cannot be used [9]. We rec-
ommend that ciprofloxacin should not be used as a first
line treatment option for UTIs as continuous increases in
resistance to ciprofloxacin further weaken the effective-
ness of this drug.
Additional findings from the meta-analysis showed that
resistance was significantly higher in developing countries
compared to developed countries. A major factor account-
ing for this difference is the use of over the counter or
non-prescription antibiotics which occur commonly in de-
veloping countries [62, 63]. Although this review did not
directly consider antimicrobial resistance in relation to pre-
scribing for the included studies, evidence shows that over
the counter or non-prescription use results in unnecessary
and excessive use of antibiotics. Some of the included stud-
ies in our review clearly state that there are no restrictions
for over the counter prescribing of antimicrobials within
their countries [29, 64–73]. A recent systematic review in-
vestigating global non-prescription antimicrobial use found
that resistance was common in communities with frequent
non-prescription antimicrobial use [74]. Non-prescription
use was highest in Africa, Asia and Middle East at 100, 58
and 39 % respectively [74]. In our review, further analyses
by region showed that Asia had the highest pooled resist-
ance to ciprofloxacin with a significantly higher resistance
in Africa, Asia and Middle East combined compared with
Europe and the Americas. Our finding is supported by a
recent paper by Dalhoff [75] reporting that fluoroquino-
lone resistance was highest in the Asia-Pacific region and
moderate to low in Europe and North America. Further-
more, there is evidence to show that countries that have
developed control policies to regulate non-prescription use
have seen a decrease in antimicrobial use and resistance
rates [74]. Based on our findings, we therefore emphasize
the need for the development of policies restricting over
the counter antimicrobial use in countries that do not have
such policies thereby contributing to the prevention of
patient morbidity and mortality associated with resistant
infections. It is noteworthy to mention that another im-
portant factor contributing to antimicrobial resistance is
the use of antibiotics in livestock for growth promotion
[76]. Extensive antimicrobial use in food animal produc-
tion has been associated with antimicrobial resistance glo-
bally [76]. This has considerable implications for human
health with the need to protect the efficacy of these antimi-
crobials to ensure their effectiveness for the treatment of
humans.
A large variation in ciprofloxacin resistance was found
in studies reporting on community-acquired UTI. This
variation highlights the significance of local resistance
monitoring to guide the development of local antibiotic
guidelines. The random effects meta-regression model
confirmed that a number of factors significantly accounted
for the variations in ciprofloxacin resistance. These in-
clude economy (developed and developing), Asia as a re-
gion, year of study, studies including only children and
studies with a high risk of bias. The first three factors have
been discussed in detail in the preceding paragraphs. We
found that resistance was lower in studies involving only
children. This finding is in line with a number of studies
which have compared resistance in adults and children
showing significantly higher ciprofloxacin resistance in
adults compared to children [77, 78]. Increased age has
also been shown to be significantly associated with cipro-
floxacin resistance [6, 47]. Given that children are less ex-
posed to antimicrobials with limited ciprofloxacin use in
the paediatric age group, this finding is expected [77–79].
Although the importance of intrafamilial cross-infection
of resistant pathogens is yet to be confirmed, it has been
suggested that fluoroquinolone resistance may to some
extent be dependent on cross-infection with transfer from
adults to children [78]. Given this assumption, it is neces-
sary to also monitor resistance levels in children to pre-
vent further resistance development in this vulnerable age
group. Other likely causes of higher resistance in adults
may be the greater likelihood of comorbidities with more
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frequent contact with healthcare settings [47]. The last
factor found to account for heterogeneity between studies
was high risk of bias. Most of the studies included in the
review were found to have a high risk of bias as assessed
using the NOS scale. These studies lacked methodological
rigour including absence of the inclusion of possible con-
founding factors (such as age, sex and previous use of an
antimicrobial) in the design and analysis of the studies.
The poor reporting of observational studies poses limita-
tions for conducting meta-analysis of these studies. Better
presentation of definitions would enable inclusion in sys-
tematic reviews of some categories that had to be ex-
cluded in this review. Observational studies are more
prone to confounding bias [80] further emphasizing the
need for adherence to reporting guidelines such as such as
that based on the Strengthening the Reporting of Obser-
vational Studies in Epidemiology (STROBE) Statement
[81] to ensure clear and comprehensive reporting prior to
publication acceptance. The poor quality of many studies
initially retrieved for this review resulted in a large num-
ber being excluded. Therefore the information provided in
this systematic review and meta-analysis of 54 observa-
tional studies may not sufficiently address ciprofloxacin
resistance globally but may provide satisfactory evidence
to inform future interventions.
In addition, this systematic review highlights the weak-
nesses in the quality of antimicrobial resistance data that
are being collected in various regions. These weaknesses
have implications for development of effective surveil-
lance systems to monitor resistance globally and strat-
egies to prevent further resistance development. The
need for the implementation of national and global sur-
veillance systems to detect and continuously monitor
AMR cannot be overemphasized. These systems would
enable prospective studies to be conducted and would
play a major role in curtailing the widespread effect of
antimicrobial resistance and help healthcare providers in
deciding on the most appropriate empirical therapy for
UTI to ensure proper management of patients. Govern-
ments need to put in place policies to restrict over the
counter use and inappropriate prescribing of ciprofloxa-
cin and other antimicrobials to prevent further develop-
ment of resistance.
Strengths and limitations
There are a number of notable strengths to our review.
To our knowledge, this is the first systematic review to
compare the overall prevalence of ciprofloxacin resist-
ance in community- and hospital-acquired E. coli UTI.
We undertook a comprehensive literature search process
to identify and screen articles against eligibility criteria.
Given that generic versions of ciprofloxacin were first
marketed at different times in various countries, our
choice of 2004 as the start date was therefore made on
the basis of changes in the epidemiology of antimicrobial
resistant pathogens which had resulted in changes to
treatment regimens. A further strength of this systematic
review is the development of a peer reviewed, registered
protocol prior to undertaking the review. For studies to
be included in the review, they were restricted to those that
used a standard laboratory UTI criterion of ≥105 cfu/mL as
recommended by the CDC. Although applying the inter-
nationally recognised CDC criteria may definitely be con-
sidered a strength as it ensures the quality and uniformity
of included studies, this criterion limited the number of
hospital-acquired UTI studies included in our systematic
review. Despite this, resistance was still found to be higher
in the hospital setting compared to the community setting
similar to published studies. While lower counts of uro-
pathogens are relevant for acute episodes of uncomplicated
cystitis, the use of different colony counts makes compari-
son of data between studies difficult. Including all urinary
E.coli isolates was considered but not done because this
existing surveillance criterion (≥105 cfu/mL and 48 h cut
off) is usually applied to defining infections not isolates.
Also, including all isolates carries the risk of including du-
plicates. This approach poses some degree of ascertainment
bias as our systematic review focuses on laboratory identi-
fied UTIs which may not only underestimate the total
number of UTIs but also lead to selection of samples from
complicated cases thereby overestimating resistance. An-
other limitation is the wide variation of resistance estimates
between studies and the inclusion of studies having sub-
stantial clinical and methodological heterogeneity. Visual
inspection of the funnel plot (Fig. 6) showed asymmetry
suggesting evidence of publication bias, with studies report-
ing high resistance rates being more likely to be published
posing a limitation to this review. Also, the quality and risk
of bias of some of the studies included in the review
were assessed as high. These limitations were addressed
by undertaking a random effects meta-analysis with subse-
quent subgroup analyses and random effects meta-
regression to explain the sources of heterogeneity. For
studies in which the design was not stated, the review au-
thors faced difficulties in categorising such studies hence
some of these studies were grouped as non-classifiable.
These studies did not provide clear and explicit informa-
tion on the methods used for conducting the studies. This
emphasizes the need for implementation and adherence
to clear reporting standards prior to publication of papers.
Furthermore, in some included studies, adjustments were
not made for important confounding factors relevant to
antimicrobial resistance such as antibiotic use and patient
demographics including age and sex. For this systematic
review, studies on samples obtained from emergency de-
partment (ED) patients were classified as community-
acquired samples. Included papers did not provide any in-
formation on whether some of these patients may have
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returned from a recent hospitalisation and represented to
the ED. Ideally, these should be considered as hospital-
acquired infections as some of these patients may have
been discharged in the previous 48 h. For the purpose of
this review and to overcome inherent variations in how in-
dividual studies have defined these patients, we classified
all papers reporting on ED patients as community-
acquired UTI studies. It was not possible to determine the
potential effect of samples obtained from nursing home or
residential aged care studies on the pooled resistance be-
cause this participant group did not meet the inclusion
criteria for analysis. Furthermore, classification of this set-
ting as hospital or community remains controversial. Fi-
nally, validity issues may have arisen from the use of
different antimicrobial susceptibility test and interpret-
ation methods with differing breakpoints which tend to
change over the years. To date, there is still no worldwide
consensus on the most suitable antimicrobial susceptibil-
ity testing method with the fact that various countries and
even laboratories within the same country use different
tests and interpretative criteria. Subgroup analysis for
AST method was considered but not done because almost
all studies used the disk diffusion method and CLSI
criteria.
Conclusions
Ciprofloxacin resistance in E. coli UTI is increasing. The
use of this antimicrobial agent as empirical therapy for
UTI should be reconsidered and efforts should be made to
limit its use to clinical conditions for which there are clear
therapeutic indications. Policy restrictions on ciprofloxacin
use need to be developed and enforced especially in devel-
oping countries that are yet to have such policies put in
place. Further research is needed to describe ciprofloxacin
resistance in hospital-acquired E. coli UTI using widely ac-
cepted definitions.
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